The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

biobdx.com

Stage

Acquired | Acquired

Total Raised

$42.55M

About BioBehavioral Diagnostics Company

BioBehavioral Diagnostics (BioBDx) aims to develop, manufacture, and market diagnostic systems for the quantitative assessment of behavioral disorders, including the measurement of medication response and the prediction of therapeutic efficacy for a patient. BioBehavioral Diagnostics Company is also a manufacturer of the Quotient ADHD System, a tool that aids in the objective and accurate assessment of ADHD symptoms.

BioBehavioral Diagnostics Company Headquarter Location

2250 Hickory Road Sutie 216

Plymouth Meeting, Pennsylvania, 19462,

United States

617-213-3013

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

BioBehavioral Diagnostics Company Patents

BioBehavioral Diagnostics Company has filed 2 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/11/2011

6/12/2012

Grant

Application Date

7/11/2011

Grant Date

6/12/2012

Title

Related Topics

Status

Grant

Latest BioBehavioral Diagnostics Company News

Pearson Acquires ADHD Testing Company BioBehavioral Diagnostics

Aug 28, 2013

The Quotient ADHD Test offers physicians, mental health professionals and educators objective assessment of ADHD. Bloomington, MN (PRWEB) August 27, 2013 Pearson today announced the acquisition of substantially all of the assets of the BioBehavioral Diagnostics Company (BioBDx) , the developer and marketer of the Quotient® System, the first U.S. FDA-cleared tool for the objective measurement of hyperactivity, impulsivity and inattention as an aid in the assessment of attention deficit hyperactivity disorder (ADHD). The Quotient ADHD Test provides quantitative analysis of motion, attention and shifts in attention states, bringing a new level of rigor and reliability to ADHD diagnosis and remediation. Focusing on a highly prevalent condition known to pose serious challenges to educational outcomes, this acquisition marks a strategic entry into healthcare markets for Pearson, the world leader in clinical and educational assessment for learners. The Quotient ADHD Test quantifies the severity of deficits in brain functions related to the symptoms of ADHD and helps clinicians to accurately diagnose and efficiently manage the condition through repeat assessments at critical decision points. The Quotient ADHD Test is currently used in pediatric, neurology and psychiatry offices throughout the United States. “We are taking immediate steps to strengthen support for current Quotient customers and expand our outreach to healthcare professionals,” said Aurelio Prifitera, President and CEO of Pearson Clinical Assessment. “We also look forward to introducing the Quotient ADHD Test to mental health and education professionals in both clinical and school settings.” ADHD is the most common neurobehavioral condition in children, and symptoms persist into adulthood in approximately 60 percent of cases. It affects approximately 6.7 million children and adolescents and nearly 15 million adults in the United States. ADHD makes it difficult for a person to control behavior and may have serious consequences, including failure in school, family stress and disruption, depression, problems with relationships, substance abuse, delinquency, risk for accidental injuries and job failure. Early identification and effective treatment are extremely important. As such, ADHD is a condition that is central to Pearson’s vision to meet the educational needs across a spectrum of individuals. Byron Hewett, Chairman and CEO of BioBDx, said, “As a part of Pearson, Quotient product development, clinical trials and commercial activities will be funded more robustly and the product will be offered to an even broader audience. This will accelerate awareness and adoption, improve efficiency of patient visits and, ultimately, raise the standard of care for ADHD. Our team has deep expertise in the diagnostic world, and we believe Pearson will benefit from that expertise in the years to come.” About Pearson Pearson is the world’s leading learning company, providing educational materials and services and business information through the Financial Times Group. Pearson serves learners of all ages around the globe, employing 41,000 people in more than 70 countries. For more information, visit http://www.pearson.com . For more information, press only: Pearson: Lisa Wolfe, lwolfe(at)lwolfe(dot)com

  • Where is BioBehavioral Diagnostics Company's headquarters?

    BioBehavioral Diagnostics Company's headquarters is located at 2250 Hickory Road, Plymouth Meeting.

  • What is BioBehavioral Diagnostics Company's latest funding round?

    BioBehavioral Diagnostics Company's latest funding round is Acquired.

  • How much did BioBehavioral Diagnostics Company raise?

    BioBehavioral Diagnostics Company raised a total of $42.55M.

  • Who are the investors of BioBehavioral Diagnostics Company?

    Investors of BioBehavioral Diagnostics Company include Pearson, Sevin Rosen Funds, Tullis Dickerson, Tullis Health Investors and Qualifying Therapeutic Discovery Project.

  • Who are BioBehavioral Diagnostics Company's competitors?

    Competitors of BioBehavioral Diagnostics Company include Brain Tunnelgenix Technologies, INRange Systems, Acelity, Med-Tek, WaveTec Vision and 13 more.

You May Also Like

N
NDO Surgical

Medical devices for the treatment of severe gastrointestinal disorders

P
Proneuron Biotechnologies

Biopharmaceutical products for the of spinal cord injuries and other central nervous system disorders.

P
Patton Medical Devices

Patton Medical Devices is a medical device company developing: I-Port Injection Port.The i-port® is a simple medication delivery device that relieves the hardships of daily injections for individuals with diabetes and other chronic conditions. Developed by KK Patton, a woman with diabetes, the i-port® aims to improve one's health and quality of life.

L
LifePoint

Lifepoint is a medical technology company developing rapid and cost effective, non-invasive, on-site diagnostic products. The Company has developed and will continue to develop patented, proprietary technologies utilizing saliva as a test specimen to provide blood equivalent diagnostic results without the need for blood or urine.

E
Es Vascular

ES Vascular Ltd. developed first ever surgical stapling devices for endovascular surgery. These devices aim to transform vascular surgery by shortening procedural times, and by simplifying and potentially increasing the safety of the most common vascular interventions. The company is currently developing three product lines for open AAA, endovascular AAA and Femoro-Pop bypass procedures. Its first products are anticipated to enter the market in 2008.nCompany Snapshotn Started in 2000 in Israel by Prof. Shifrin together with group of engineers and leading vascular surgeons from the US and Europe;n Developed a ever vascular stapling technology for stapling synthetic grafts to the aortan Developed endovascular devices for EVAR and SFA procedures

L
Ligon Discovery

Ligon Discovery is a drug discovery company built around the firm's primary technology platform, Small-Molecule Microarrays (SMMs).

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.